Scarica l'app Stockscreener
12.88
0.54%
0.0786
Precedente Chiudi:
$12.80
Aprire:
$12.8
Volume 24 ore:
160.19K
Relative Volume:
0.06
Capitalizzazione di mercato:
$4.11B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
34.46
EPS:
0.3737
Flusso di cassa netto:
$225.64M
1 W Prestazione:
+1.73%
1M Prestazione:
+7.69%
6M Prestazione:
+28.69%
1 anno Prestazione:
+68.00%
Intervallo 1D:
$12.72
$12.95
Intervallo di 1 settimana:
$12.35
$13.03
Portata 52W:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.88 | 4.06B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.73 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
114.64 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.365 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.09 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.78 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge? - simplywall.st
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For - StockStory
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo! Finance Canada
AMRX Should I Buy - Intellectia AI
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Quantisnow
Amneal 2026-2027 Upside From Biosimilars Scale - Zacks Investment Research
AMRX Valuation: What 1.69x Sales Means for Investors - Yahoo Finance
AMRX Growth Drivers: Generics, Biosimilars, and Crexont - Yahoo Finance Australia
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock - Yahoo Finance
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story - Sahm
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal - MSN
Amneal Acquires Kashiv BioSciences for $750 Million Upfront - HarianBasis.co
Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push - MarketBeat
AMRX Price Today: Amneal Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
2DT Stock Price and Chart — TRADEGATE:2DT - TradingView
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Sahm
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):